In situ MUC1-specific CAR engineering of tumor-supportive macrophages stimulates tumoricidal immunity against pancreatic adenocarcinoma

Liu, Ying; Jing, Weiqiang; Zhang, Jing; Chen, Chen; Gao, Lin; Shi, Chongdeng; Li, Anning; Sun, Peng; Zhang, Rui; Yang, Zhenmei; Tang, Chunwei; Du, Wei; Dong, Yuanmin; Xu, Jie; Zhao, Kun; Jiang, Xinyi

doi:10.1016/j.nantod.2023.101805

Cited by 6 publications

(2 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Later, following the same design principle, the research group successfully reprogrammed tumor-associated macrophages to CAR-M against ErbB2, or mucin 1 tumor antigens. [74,75] Most recently, the same group reported a unique implant nanoparticle that locoregionally yielded CAR-M targeting Staphylococcus aureus to prevent periprosthetic joint infection. [76]…”

Section: Nanomaterials For Plasmid Dna Deliverymentioning

confidence: 99%

In Situ Reprogramming of Immune Cells Using Synthetic Nanomaterials

Nie,

Qin,

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

In the past decade, adoptive cell therapy with chimeric antigen receptor‐T (CAR‐T) cells has revolutionized cancer treatment. However, the complexity and high costs involved in manufacturing current adoptive cell therapy greatly inhibit its widespread availability and access. To address this, in situ cell therapy, which directly reprograms immune cells inside the body, has recently been developed as a promising alternative. Here, we provide an overview of the recent progress in the development of synthetic nanomaterials to deliver plasmid DNA or mRNA for in situ reprogramming of T cells and macrophages, focusing especially on in situ CAR therapies. Also, we discuss the main challenges for in situ immune cell reprogramming and propose some approaches to overcome these barriers to fulfill the clinical applications.This article is protected by copyright. All rights reserved

show abstract

Section: Nanomaterials For Plasmid Dna Deliverymentioning

confidence: 99%

In Situ Reprogramming of Immune Cells Using Synthetic Nanomaterials

Nie,

Qin,

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

show abstract

“…Recently, a mucin 1-specific CAR was constructed to engineer the macrophages in tumors. The edited macrophages displayed significantly improved phagocytosis, antigen-presenting activity, and activation of cytotoxic T lymphocytes to combat pancreatic adenocarcinoma (PAAD) [129]. Interestingly, the locoregional CAR-Ms were also generated to induce bactericidal immunologic activity at the disease site [130].…”

Section: In Situ Gene Editing For Car-msmentioning

confidence: 99%

A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy

Li,

Geng,

Dong

et al. 2024

Mol Cancer

View full text Add to dashboard Cite

Significant advancements have been made in the application of chimeric antigen receptor (CAR)-T treatment for blood cancers during the previous ten years. However, its effectiveness in treating solid tumors is still lacking, necessitating the exploration of alternative immunotherapies that can overcome the significant challenges faced by current CAR-T cells. CAR-based immunotherapy against solid tumors shows promise with the emergence of macrophages, which possess robust phagocytic abilities, antigen-presenting functions, and the ability to modify the tumor microenvironment and stimulate adaptive responses. This paper presents a thorough examination of the latest progress in CAR-M therapy, covering both basic scientific studies and clinical trials. This study examines the primary obstacles hindering the realization of the complete potential of CAR-M therapy, as well as the potential strategies that can be employed to overcome these hurdles. With the emergence of revolutionary technologies like in situ genetic modification, synthetic biology techniques, and biomaterial-supported gene transfer, which provide a wider array of resources for manipulating tumor-associated macrophages, we suggest that combining these advanced methods will result in the creation of a new era of CAR-M therapy that demonstrates improved efficacy, safety, and availability. Graphical Abstract

show abstract